Poly (caprolactone) microparticles and chitosan thermogels based injectable formulation of etoricoxib for the potential treatment of osteoarthritis

Arunkumar, P.; Indulekha, S.; Vijayalakshmi, S.; Srivastava, Rohit

doi:10.1016/j.msec.2015.12.039

Cited by 39 publications

(22 citation statements)

References 43 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many different thermo‐responsive gels have been investigated for use in biomedical applications including cellulose derivatives, chitosan and glycerophosphate and poly( N ‐isopropylacrylamide) copolymers as well as those mentioned above. Only a small number have been investigated for joint conditions, however, including chitosan and PCLA–PEG–PCLA . One consideration is that network formation occurs entirely through noncovalent interactions and their disruption can lead to early disintegration of the gel in the body and/or compromised mechanical properties .…”

Section: Introductionmentioning

confidence: 99%

Effect of drug loading on the properties of temperature‐responsive polyester–poly(ethylene glycol)–polyester hydrogels

Prince

Villamagna

Hopkins

et al. 2019

Polymer International

View full text Add to dashboard Cite

Hydrogels that can undergo gelation upon injection in vivo are promising systems for the site-specific delivery of drugs. In particular, some thermo-responsive gels require no chemical additives but simply gel in response to a change from a lower temperature to physiological temperature (37 ∘ C). The gelation mechanism does not involve covalent bonds, and it is possible that incorporation of drugs into the hydrogel could disrupt gelation. We investigated the incorporation of drugs into thermo-responsive hydrogels based on poly( -caprolactone-co-lactide)-block-poly(ethylene glycol)-block-poly( -caprolactone-co-lactide) (PCLA-PEG-PCLA). Significant differences in properties and in the response to incorporation of the anti-inflammatory drug celecoxib (CXB) were observed as the PEG block length was varied from 1500 to 3000 g mol −1 . Linear viscoelastic moduli of a PCLA-PEG-PCLA hydrogel containing a 2000 g mol −1 PEG block were least affected by the incorporation of CXB and this gel also exhibited the slowest release of CXB, so the incorporation of phenylbutazone, methotrexate, ibuprofen, diclofenac and etodolac was also investigated for this hydrogel. Different drugs resulted in varying degrees of syneresis of the hydrogels, suggesting that they interact with the polymer networks in different ways. In addition, the drugs had varying effects on the viscoelastic and compressive moduli of the gels. The results showed that the effects of drug loading on the properties of thermo-responsive hydrogels can be substantial and depend on the drug. For applications such as intra-articular drug delivery, in which the mechanical properties of the hydrogel are important, these effects should thus be studied on a case-by-case basis.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of drug loading on the properties of temperature‐responsive polyester–poly(ethylene glycol)–polyester hydrogels

Prince

Villamagna

Hopkins

et al. 2019

Polymer International

View full text Add to dashboard Cite

show abstract

“… 11 , 84 Also, the in vivo biocompatibility of microparticles associated with their derivatives/byproducts and the possible fragmentation makes it difficult to get the FDA approval. 19 , 53 , 85 …”

Section: Delivery Vehicles Of Therapeutic Moleculesmentioning

confidence: 99%

Intra-articular biomaterials-assisted delivery to treat temporomandibular joint disorders

et al. 2018

View full text Add to dashboard Cite

The temporomandibular joint disorder, also known as myofascial pain syndrome, is considered one of the prevalent chronic pain diseases caused by muscle inflammation and cartilage degradation in head and neck, and thus influences even biopsychosocial conditions in a lifetime. There are several current treatment methodologies relieving inflammation and preventing degradation of the joint complex. One of the promising non-surgical treatment methods is an intra-articular injection of drugs such as corticosteroids, analgesics, and anti-depressants. However, the side effects of drugs due to frequent injections and over-doses, including dizziness, dry mouth, and possible drug dependency are considered limitations. Thus, the delivery of therapeutic molecules through the use of nano/microparticles is currently considered as a promising strategy primarily due to the controlled release. This review highlights the nano/microparticle systems for effective intra-articular therapeutics delivery to prevent cartilage degradation and protect subchondral bone in a temporomandibular joint.

show abstract

“…Instead, controlled drug‐release from a depot can offer advantages such as reduced dosing frequency, lower doses, and reduced side effects. Several different drug‐delivery vehicles, both slow release and bioresponsive, have been developed to optimize treatment of inflammatory diseases and cancer . The bioresponsive drug‐delivery vehicles enhanced drug efficacy compared to nonresponsive controls, delivering drugs to established chronic inflammatory disease models such as multiple sclerosis (MS) .…”

Section: Introductionmentioning

confidence: 99%

Disease‐Triggered Drug Release Effectively Prevents Acute Inflammatory Flare‐Ups, Achieving Reduced Dosing

Stubelius

Sheng

Lee

et al. 2018

Small

View full text Add to dashboard Cite

For conditions with inflammatory flare-ups, fast drug-release from a depot is crucial to reduce cell infiltration and prevent long-term tissue destruction. While this concept has been explored for chronic diseases, preventing acute inflammatory flares has not been explored. To address this issue, a preventative inflammation-sensitive system is developed and applied to acute gout, a condition where millions of inflammatory cells are recruited rapidly, causing excruciating and debilitating pain. Rapid drug release is first demonstrated from a pH-responsive acetalated dextran particle loaded with dexamethasone (AcDex-DXM), reducing proinflammatory cytokines in vitro as efficiently as free drug. Then, using the air pouch model of gout, mice are pretreated 24 h before inducing inflammation. AcDex-DXM reduces overall cell infiltration with decreased neutrophils, increases monocytes, and diminishes cytokines and chemokines. In a more extended prophylaxis model, murine joints are pretreated eight days before initiating inflammation. After quantifying cell infiltration, only AcDex-DXM reduces the overall joint inflammation, where neither free drug nor a conventional drug-depot achieves adequate anti-inflammatory effects. Here, the superior efficacy of disease-triggered drug-delivery to prevent acute inflammation is demonstrated over free drug and slow-release depots. This approach and results promise exciting treatment opportunities for multiple inflammatory conditions suffering from acute flares.

show abstract

Poly (caprolactone) microparticles and chitosan thermogels based injectable formulation of etoricoxib for the potential treatment of osteoarthritis

Cited by 39 publications

References 43 publications

Effect of drug loading on the properties of temperature‐responsive polyester–poly(ethylene glycol)–polyester hydrogels

Effect of drug loading on the properties of temperature‐responsive polyester–poly(ethylene glycol)–polyester hydrogels

Intra-articular biomaterials-assisted delivery to treat temporomandibular joint disorders

Disease‐Triggered Drug Release Effectively Prevents Acute Inflammatory Flare‐Ups, Achieving Reduced Dosing

Contact Info

Product

Resources

About